Cargando…
Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review
Lung adenocarcinoma is one of the most common solid tumors, and diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of adult non-Hodgkin’s lymphoma. Although extra-nodular lesions are frequently observed in patients with DLBCL, urinary bladder involvement is rare. We report...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894961/ https://www.ncbi.nlm.nih.gov/pubmed/35226514 http://dx.doi.org/10.1177/03000605221081672 |
_version_ | 1784662805969895424 |
---|---|
author | Xu, Feng Liang, Ying Mo, Wen-Bin Yan, Xiao-Jing Zhang, Rui |
author_facet | Xu, Feng Liang, Ying Mo, Wen-Bin Yan, Xiao-Jing Zhang, Rui |
author_sort | Xu, Feng |
collection | PubMed |
description | Lung adenocarcinoma is one of the most common solid tumors, and diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of adult non-Hodgkin’s lymphoma. Although extra-nodular lesions are frequently observed in patients with DLBCL, urinary bladder involvement is rare. We report the case of a 77-year-old woman with lung adenocarcinoma who was diagnosed with a second primary bladder DLBCL, 9 months after treatment with molecular targeted drugs. Simultaneous therapies for her lymphoma with lenalidomide and rituximab and a tyrosine kinase inhibitor therapy for her lung cancer were both effective. This result was consistent with previous reports suggesting that patients unable to tolerate intensive chemotherapy could benefit from targeted therapies. Current research into the use of lenalidomide for the treatment of lymphomas and solid tumors is promising in terms of exploring immunotherapy as an alternative option for patients with concurrent solid tumors and lymphomas who have poor tolerance to radiotherapy and chemotherapy. |
format | Online Article Text |
id | pubmed-8894961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-88949612022-03-05 Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review Xu, Feng Liang, Ying Mo, Wen-Bin Yan, Xiao-Jing Zhang, Rui J Int Med Res Case Report Lung adenocarcinoma is one of the most common solid tumors, and diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of adult non-Hodgkin’s lymphoma. Although extra-nodular lesions are frequently observed in patients with DLBCL, urinary bladder involvement is rare. We report the case of a 77-year-old woman with lung adenocarcinoma who was diagnosed with a second primary bladder DLBCL, 9 months after treatment with molecular targeted drugs. Simultaneous therapies for her lymphoma with lenalidomide and rituximab and a tyrosine kinase inhibitor therapy for her lung cancer were both effective. This result was consistent with previous reports suggesting that patients unable to tolerate intensive chemotherapy could benefit from targeted therapies. Current research into the use of lenalidomide for the treatment of lymphomas and solid tumors is promising in terms of exploring immunotherapy as an alternative option for patients with concurrent solid tumors and lymphomas who have poor tolerance to radiotherapy and chemotherapy. SAGE Publications 2022-02-28 /pmc/articles/PMC8894961/ /pubmed/35226514 http://dx.doi.org/10.1177/03000605221081672 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Xu, Feng Liang, Ying Mo, Wen-Bin Yan, Xiao-Jing Zhang, Rui Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review |
title | Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review |
title_full | Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review |
title_fullStr | Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review |
title_full_unstemmed | Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review |
title_short | Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review |
title_sort | concurrent lung adenocarcinoma and bladder diffuse large b-cell lymphoma: a case report and literature review |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894961/ https://www.ncbi.nlm.nih.gov/pubmed/35226514 http://dx.doi.org/10.1177/03000605221081672 |
work_keys_str_mv | AT xufeng concurrentlungadenocarcinomaandbladderdiffuselargebcelllymphomaacasereportandliteraturereview AT liangying concurrentlungadenocarcinomaandbladderdiffuselargebcelllymphomaacasereportandliteraturereview AT mowenbin concurrentlungadenocarcinomaandbladderdiffuselargebcelllymphomaacasereportandliteraturereview AT yanxiaojing concurrentlungadenocarcinomaandbladderdiffuselargebcelllymphomaacasereportandliteraturereview AT zhangrui concurrentlungadenocarcinomaandbladderdiffuselargebcelllymphomaacasereportandliteraturereview |